Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer

被引:40
作者
Deitelzweig, Steven [1 ,2 ]
V. Keshishian, Allison [3 ,4 ]
Zhang, Yan [5 ]
Kang, Amiee [5 ]
Dhamane, Amol D. [5 ]
Luo, Xuemei [6 ]
Klem, Christian [5 ]
Ferri, Mauricio [5 ]
Jiang, Jenny [5 ]
Yuce, Huseyin [4 ,7 ]
Lip, Gregory Y. H. [8 ,9 ]
机构
[1] Ochsner Clin Fdn, Dept Hosp Med, New Orleans, LA USA
[2] Univ Queensland, Sch Med, Ochsner Clin Sch, New Orleans, LA USA
[3] STATinMED Res, Ann Arbor, MI USA
[4] CUNY, New York City Coll Technol, New York, NY USA
[5] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[6] Pfizer Inc, Groton, CT USA
[7] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[8] Univ Liverpool, Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[9] Aalborg Univ, Aalborg Thrombosis Res Unit, Dept Clin Med, Aalborg, Denmark
来源
JACC: CARDIOONCOLOGY | 2021年 / 3卷 / 03期
关键词
active cancer; anticoagulants; bleeding; nonvalvular atrial fibrillation; stroke; BLEEDING COMPLICATIONS; WARFARIN; DIAGNOSIS; APIXABAN; VALIDITY; INSIGHTS; STROKE; CODES;
D O I
10.1016/j.jaccao.2021.06.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Patients with cancer are more likely to develop nonvalvular atrial fibrillation (NVAF). Currently there are no definitive clinical trials or treatment guidelines for NVAF patients with concurrent cancer. OBJECTIVES This subgroup analysis of the ARISTOPHANES study compared the risk of stroke/systemic embolism (stroke/SE) and major bleeding (MB) among NVAF patients with active cancer who were prescribed non-vitamin K antagonist oral anticoagulants (NOACs) or warfarin. METHODS A retrospective observational study was conducted in NVAF patients with active cancer who newly initiated apixaban, dabigatran, rivaroxaban, or warfarin from January 1, 2013, through September 30, 2015, with the use of Medicare and 4 U.S. commercial claims databases. Cox models were used to estimate the risk of stroke/SE and MB in the pooled propensity score-matched cohorts. RESULTS A total of 40,271 patients were included, with main cancer types of prostate (29%), female breast (17%), genitourinary (14%), and lung (13%). Compared with warfarin, apixaban was associated with a tower risk of stroke/SE (hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.45-0.78) and MB (HR: 0.58; 95% CI: 0.50-0.68); dabigatran and rivaroxaban had similar risks of stroke/SE (dabigatran: HR: 0.88 [95% CI: 0.54-1.41]; rivaroxaban: HR: 0.82 [95% CI: 0.62-1.08]) and MB (dabigatran: HR: 0.76 [95% CI: 0.57-1.01]; rivaroxaban: HR: 0.95 [95% 0: 0.85-1.06]). Risks of stroke/SE and MB varied among NOAC-NOAC comparisons, white consistent treatment effects were seen for all treatment comparisons across key cancer types. CONCLUSIONS Among this cohort of NVAF patients with active cancer, the risk of stroke/SE and MB varied among oral anticoagulants and were consistent across cancer types. (C) 2021 Published by Elsevier on behalf of the American College of Cardiology Foundation.
引用
收藏
页码:411 / 424
页数:14
相关论文
共 50 条
  • [21] Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis
    Durand, Madeleine
    Schnitzer, Mireille E.
    Pang, Menglan
    Carney, Greg
    Eltonsy, Sherif
    Filion, Kristian B.
    Fisher, Anat
    Jun, Min
    Kuo, I. Fan
    Matteau, Alexis
    Paterson, J. Michael
    Quail, Jacqueline
    Renoux, Christel
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) : 2589 - 2601
  • [22] Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
    Mueller, Tanja
    Alvarez-Madrazo, Samantha
    Robertson, Chris
    Wu, Olivia
    Bennie, Marion
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (02) : 422 - 431
  • [23] Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data
    Enomoto, Aya
    Mano, Yasunari
    Kawano, Yohei
    Nishikawa, Tomoki
    Aoyama, Takao
    Sasaki, Yoshiyuki
    Nagata, Masashi
    Takahashi, Hiromitsu
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2021, 44 (09) : 1294 - 1302
  • [24] Oral Anticoagulants in Patients with Atrial Fibrillation and Active Cancer
    Yu, Li-Ying
    Liu, Yen-Wen
    Chou, Tzu-Yu
    Liu, Yi-Chia
    Su, Pei-Fang
    Liu, Ping-Yen
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (07)
  • [25] Selection of Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation
    Deguchi, Ichiro
    Tanahashi, Norio
    Takao, Masaki
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2018, 27 (10) : 2627 - 2631
  • [26] Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
    Weir, Matthew R.
    Chen, Yen-Wen
    He, Jinghua
    Bookhart, Brahim
    Campbell, Alicia
    Ashton, Veronica
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (11)
  • [27] Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation
    Alexandros Briasoulis
    Amgad Mentias
    Alexander Mazur
    Paulino Alvarez
    Enrique C. Leira
    Mary S. Vaughan Sarrazin
    Cardiovascular Drugs and Therapy, 2021, 35 : 261 - 272
  • [28] Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation
    Binding, Casper
    Blanche, Paul
    Lip, Gregory Y. H.
    Kamper, Anne-Lise
    Lee, Christina J. Y.
    Staerk, Laila
    Gislason, Gunnar
    Torp-Pedersen, Christian
    Olesen, Jonas Bjerring
    Bonde, Anders Nissen
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (03) : 210 - 218
  • [29] Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
    Dhamane, Amol D.
    Ferri, Mauricio
    Keshishian, Allison
    Russ, Cristina
    Atreja, Nipun
    Gutierrez, Cynthia
    Emir, Birol
    Yuce, Huseyin
    Di Fusco, Manuela
    ADVANCES IN THERAPY, 2023, 40 (03) : 887 - 902
  • [30] Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
    Amol D. Dhamane
    Mauricio Ferri
    Allison Keshishian
    Cristina Russ
    Nipun Atreja
    Cynthia Gutierrez
    Birol Emir
    Huseyin Yuce
    Manuela Di Fusco
    Advances in Therapy, 2023, 40 : 887 - 902